Abbott Laboratories is expanding its cardiovascular portfolio in India with the introduction of an advanced stent technology, aimed at improving treatment outcomes and supporting doctors in managing complex heart conditions across diverse patient populations.
Abbott Laboratories has confirmed the launch of its latest-generation XIENCE Skypoint stent in India. Designed to reach difficult areas within arteries, the stent helps treat a wide range of blockages, offering enhanced flexibility and precision for doctors handling complex cardiovascular procedures.
The XIENCE Skypoint stent features a slim and smooth delivery system, making it easier to guide through heart arteries, including large vessels. It also includes a left main indication, enabling physicians to treat critical coronary artery segments and improving success rates in challenging interventional cardiology cases.
Abbott aims to offer the broadest matrix within its XIENCE family, supporting treatment of long lesions while reducing the number of stents required per procedure. This approach enhances efficiency, provides more treatment options for physicians, and improves patient confidence in achieving better long-term heart health outcomes.
As a diversified global healthcare company, Abbott operates across medical devices, diagnostics, branded generic pharmaceuticals, and nutrition products. Its continued innovation in cardiovascular technology reflects a strong commitment to advancing patient care and supporting healthcare systems with reliable, high-quality medical solutions worldwide.
